Bad BreathNCT07692581
A Clinical Trial to Evaluate the Effects of Larineco Remineralizing Gum on Oral Health, Breath Freshness, Tooth Sensitivity, and Gum Comfort
A study testing Larineco Remineralizing Gum in people with Bad Breath and Tooth Sensitivity, run by Larine C Corporation at 1 site in United States.
Trial summary
This is a single-group, open-label, decentralized (virtual) clinical trial evaluating the effects of Larineco Remineralizing Gum on self-reported oral health outcomes in 40 generally healthy adults aged 18-57 years who experience bad breath, sensitive teeth, or gum discomfort. Read more about this study
- Who is it for?
- Ages 18 to 65 yearsHealthy volunteers can take part
- Conditions the study is for
- Bad Breath, Tooth Sensitivity
- What is being tested?
- Larineco Remineralizing Gum
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 40 participants
- Where
- 1 siteUnited States
- Study dates
- 2 Jul 2026to Aug 2026
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 65 years
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
Who may be able to join
- Be male or female
- Be adults aged 18-57 years
- Self-reports experiencing at least one of the following oral concerns: bad breath, tooth sensitivity, or gum discomfort Generally healthy
- Able to safely chew gum-style products
- Willing to use the study product as directed, using one piece of gum per day, after the second meal of the day, and chewing thoroughly for 15 minutes before discarding, for the trial duration
- Willing to maintain current oral hygiene habits (e.g., brushing frequency, flossing routine, toothpaste product) Resides in the United States Anyone who is willing to maintain their current diet, sleep pattern, and activity levels for the duration of the trial Has reliable access to an internet-enabled device to complete remote study assessments
- Anyone willing to follow the study protocol
- Willing to store the study product as directed and keep it away from children and pets
Who cannot join
- Anyone with pre-existing chronic conditions that would prevent participants from adhering to the protocol, including oncological and mental health disorders
- Known allergy or hypersensitivity to any ingredient in the study product
- Any women who are pregnant, breastfeeding, or trying to conceive (or who will be at any point during the study period)
- Severe or unmanaged dental or oral conditions (e.g., active oral infection, extensive untreated cavities, severe periodontitis, oral ulcers, or recent oral surgery within the past 30 days)
- Loose or temporary dental work (e.g., temporary crowns, loose veneers, recently placed braces) that may be affected by chewing gummies
- Diagnosed temporomandibular joint (TMJ) disorder or significant jaw pain that would make chewing uncomfortable
Show all 12Show fewer
- Known dry mouth/xerostomia or significant mouth sensitivity that may interfere with product tolerance or assessment
- History of significant gastrointestinal sensitivity or digestive conditions that may be worsened by sugar alcohols, sweeteners, or functional ingredients
- Recent dental procedure (within the past 14 days) or planned dental work during the study period that may interfere with assessments
- Currently wearing fixed orthodontic appliances (e.g., traditional braces) that would significantly affect product use or assessments
- Currently partaking in another research study or will be partaking in any other research study for the next 30 days, and at any point during this study's duration
- Anyone who is undergoing treatment for cancer, or has had a serious illness requiring hospitalization in the last three months
Trial locations and contacts
1 site in 1 country.
About this study
This is a single-group, open-label, decentralized (virtual) clinical trial evaluating the effects of Larineco Remineralizing Gum on self-reported oral health outcomes in 40 generally healthy adults aged 18-57 years who experience bad breath, sensitive teeth, or gum discomfort. Participants will use the product once daily for 30 consecutive days and complete questionnaires at Baseline, Day 10, Day 20, and Day 30.
- Conditions
- Bad Breath, Tooth Sensitivity
- Being tested
- Larineco Remineralizing Gum
- Keywords
- Gum Discomfort
- Medical subject headings
- Halitosis, Dentin Sensitivity
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Larineco Remineralizing GumDietary supplement
All enrolled participants receive Larineco Remineralizing Gum, a commercially available chewing gum product. Participants chew one piece of gum per day, after the second meal of the day, slowly and thoroughly for 15 minutes before discarding, for 30 consecutive days.
| Study group | Role | What they receive |
|---|---|---|
| Larineco Remineralizing Gum | Experimental | Not described Receives: Dietary Supplement: Larineco Remineralizing Gum |
What is being measured
The primary outcome is the main question the study is designed to answer.
Oral Health
Change in self-reported oral health using questionnaires assessing breath freshness, tooth sensitivity, and gum comfort
Measured: Baseline, day 10, day 20, day 30
Secondary outcomes (2)
Tooth surface smoothness
Change in self-reported tooth surface smoothness via self-report questionnaire on the Citruslabs study platform.
Measured: Baseline, day 10, day 20, day 30
Mouth cleanliness
Change in self reported mouth cleanliness via self-report questionnaire on the Citruslabs study platform.
Measured: Baseline, Day 10, Day 20, and Day 30
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted9 Jul 2026
- Study start2 Jul 2026
- Primary completionAug 2026 (estimated)
- Study completionAug 2026 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Bad BreathStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Enrolment
- 40 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Larine C Corporation
- Sponsor type
- Industry (pharma, biotech, devices)
- Collaborators
- Citruslabs
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07692581
- Sponsor's protocol ID
- LARIN-67330
- Status last verified
- Jul 2026
- First submitted
- 2 Jul 2026
- Last updated
- 9 Jul 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Undecided
Study at a glance
From the registry record, last updated by the sponsor on 9 Jul 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Clinical Trial to Evaluate the Effects of Larineco Remineralizing Gum on Oral Health, Breath Freshness, Tooth Sensitivity, and Gum Comfort
- ClinicalTrials.gov ID
- NCT07692581
- Acronym / sponsor ID
- LARIN-67330
- Conditions
- Bad Breath, Tooth Sensitivity
- Keywords
- Gum Discomfort
- Study type
- Interventional
- Recruitment status
- Active, not recruiting
- Enrolment
- 40 participants (estimated)
- Lead sponsor
- Larine C CorporationIndustry (pharma, biotech, devices)
- Collaborators
- Citruslabs
- Study start
- 2 Jul 2026 (actual)
- Primary completion
- Aug 2026 (estimated)
- Study completion
- Aug 2026 (estimated)
- First posted
- 9 Jul 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This is a single-group, open-label, decentralized (virtual) clinical trial evaluating the effects of Larineco Remineralizing Gum on self-reported oral health outcomes in 40 generally healthy adults aged 18-57 years who experience bad breath, sensitive teeth, or gum discomfort. Participants will use the product once daily for 30 consecutive days and complete questionnaires at Baseline, Day 10, Day 20, and Day 30.
Study design
- Primary purpose
- Treatment
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Larineco Remineralizing Gum | Experimental | Dietary Supplement: Larineco Remineralizing Gum |
Who may qualify
- Ages
- 18 to 65 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (8 listed)
- Be male or female
- Be adults aged 18-57 years
- Self-reports experiencing at least one of the following oral concerns: bad breath, tooth sensitivity, or gum discomfort Generally healthy
- Able to safely chew gum-style products
- Willing to use the study product as directed, using one piece of gum per day, after the second meal of the day, and chewing thoroughly for 15 minutes before discarding, for the trial duration
Key exclusion criteria (12 listed)
- Anyone with pre-existing chronic conditions that would prevent participants from adhering to the protocol, including oncological and mental health disorders
- Known allergy or hypersensitivity to any ingredient in the study product
- Any women who are pregnant, breastfeeding, or trying to conceive (or who will be at any point during the study period)
- Severe or unmanaged dental or oral conditions (e.g., active oral infection, extensive untreated cavities, severe periodontitis, oral ulcers, or recent oral surgery within the past 30 days)
- Loose or temporary dental work (e.g., temporary crowns, loose veneers, recently placed braces) that may be affected by chewing gummies
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Larineco Remineralizing GumAll enrolled participants receive Larineco Remineralizing Gum, a commercially available chewing gum product. Participants chew one piece of gum per day, after the second meal of the day, slowly and thoroughly for 15 minutes before discarding, for 30 consecutive days. | Dietary supplement | Larineco Remineralizing Gum |
Primary outcome
Oral Health
Time frame: Baseline, day 10, day 20, day 30
Change in self-reported oral health using questionnaires assessing breath freshness, tooth sensitivity, and gum comfort
2 secondary outcomes
Tooth surface smoothness
Time frame: Baseline, day 10, day 20, day 30
Mouth cleanliness
Time frame: Baseline, Day 10, Day 20, and Day 30
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 9 Jul 2026.
- Individual participant dataSharing planned: Undecided
Related trials for Bad Breath
Active, not recruiting
A Clinical Trial to Evaluate the Effects of Super Liver Liquid Drops on Gut Health, Digestive Comfort, and Daily Energy Levels
Gastrointestinal Symptoms, Bloating
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Larineco Remineralizing Gum in people with Bad Breath and Tooth Sensitivity, run by Larine C Corporation at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 8 inclusion and 12 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: under way, not looking for participants, as of the sponsor's last update on 9 Jul 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Oral Health (time frame: Baseline, day 10, day 20, day 30). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 9 Jul 2026; AzTrials last refreshed its copy on 8 Nov 2026.